OnabotulinumtoxinA (botulinum toxin type-A) in the prevention of migraine

Bibliography

• Brandes JL, Saper JR, Diamond M, Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004;291:965-73
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Mathew NT, Stubits E, Nigam MR. Transformation of episodic migraine into daily headache: analysis of factors. Headache 1982;22:66-8
   PubMed Web of Science ®Google Scholar
• Mathew NT, Reuveni U, Perez F. Transformed or evolutive migraine. Headache 1987;27:102-6
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988;8(Suppl 7):1-96
   Google Scholar
• Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache 2005;45(Suppl 1):S3-13
   PubMed Web of Science ®Google Scholar
• Kurth T, Schürks M, Logroscino G, Buring JE. Migraine frequency and risk of cardiovascular disease in women. Neurology 2009;73(8):581-8
   PubMed Web of Science ®Google Scholar
• Palm-Meinders IH, Koppen H, Terwindt GM, Progression of brain white matter lesions in migraine? The 9-year follow-up population-based CAMERA-2 study. [Abstract LBOR5]. Cephalalgia 2009;49:1351
   Google Scholar
• Kruit M, Launer LJ, Ferrari M, van Buchemm MA. Infarcts in the posterior circulation territory in migraine. The population-based MRI CAMERA study. Brain 2005;128:2066-77
   Google Scholar
• Cady RK, Mathew N, Diener H-C, Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache 2009;49:216-26
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997;17:109-12
   PubMed Web of Science ®Google Scholar
• Binder WJ, Brin MF, Blitzer A, Botulinum toxin type A (BOTOX) for treatment of migraine headaches: an open-label study. Otolaryngol Head Neck Surg 2000;123:669-76
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68:343-9
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Diamond S, Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41(7):646-57
   PubMed Web of Science ®Google Scholar
• Scher AI, Stewart WF, Lipton RB. Migraine and headache: a meta-analytic approach. In: Crombie IK, editor, Epidemiology of pain. IASP Press, Seattle, WA; 1999. p. 159-70
   Google Scholar
• Cady RK. The epidemiology and pathophysiology of migraine. Manag Care 2007;16(7 Suppl 7):4-9
   PubMedGoogle Scholar
• Lipton RB, Diamond S, Reed M, Migraine diagnosis and treatment: results from the American Migraine Study II. Headache 2001;41:638-45
   PubMed Web of Science ®Google Scholar
• Diamond S, Bigal ME, Silberstein S, Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache 2007;47:355-63
   PubMed Web of Science ®Google Scholar
• Silberstein S, Diener HC, Lipton R, Epidemiology, risk factors, and treatment of chronic migraine: a focus on topiramate. Headache 2008;48:1087-95
   PubMed Web of Science ®Google Scholar
• Felber ES. Botulinum toxin in primary care medicine. J Am Osteopath Assoc 2006;106:609-14
   PubMedGoogle Scholar
• Simpson DM, Gracies J-M, Graham HK, Assessment: botulinum neurotoxin for the treatment of spasticity an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2008;70:1691-8
   PubMed Web of Science ®Google Scholar
• Bakheit AM, Fedorova NV, Skoromets AA, The beneficial antispasticity effect of botulinum toxin type A is maintained after repeated treatment cycles. J Neurol Neurosurg Psychiatry 2004;75:1558-61
   PubMed Web of Science ®Google Scholar
• Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004;44(1):35-42
   PubMed Web of Science ®Google Scholar
• Durham PL. CGRP-receptor antagonists–a fresh approach to migraine therapy? N Engl J Med 2004;350:1073-5
   PubMed Web of Science ®Google Scholar
• Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43(Suppl 1):S16-24
   PubMed Web of Science ®Google Scholar
• Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003;43(Suppl 1):S9-S15
   PubMedGoogle Scholar
• Aoki KR. Basic aspects of botulinum toxin: physiology and pharmacology of therapeutic botulinum neurotoxins. Curr Probl Dermatol 2002;30:107-16
   PubMedGoogle Scholar
• Blasi J, Chapman ER, Link E, Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365(6442):160-63
   PubMed Web of Science ®Google Scholar
• Malick A, Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 2000;15(Suppl 3):28-35
   PubMed Web of Science ®Google Scholar
• Caleo M, Antonucci F, Restani L, Mazzocchio R. A reappraisal of the central effects of botulinum neurotoxin type A: by what mechanism? J Neurochem 2009;109(1):15-24
   PubMed Web of Science ®Google Scholar
• Silberstein S, Mathew N, Saper J, Jenkins S. Botulinum toxin type A as a migraine preventive treatment. Headache 2000;40:445-50
   PubMed Web of Science ®Google Scholar
• Farinelli I, Coloprisco G, DeFillippis S, Martelletti P. Long-term benefits of botulinum toxin type A (Botox) in chronic daily headache: a five-year long experience. J Headache Pain 2006;7:407-12
   PubMedGoogle Scholar
• Aurora SK, Gawel M, Brandes JL, Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study. Headache 2007;47:486-99
   PubMed Web of Science ®Google Scholar
• Mathew NT, Jaffri SFA. A double-blind comparison of onabotulinumtoxinA (BOTOX) and topiramate (TOPAMAX) for the prophylactic treatment of chronic migraine: a pilot study. Headache 2009;49:1466-78
   PubMed Web of Science ®Google Scholar
• Freitag FG, Diamond S, Diamond M, Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache 2008;48:201-9
   PubMed Web of Science ®Google Scholar
• Blumenfeld AM, Schim JD, Chippendale TJ. Botulinum toxin type A and divalproex sodium for prophylactic treatment of episodic or chronic migraine. Headache 2008;48:210-20
   PubMed Web of Science ®Google Scholar
• Jakubowski M, McAllister PJ, Bajwa ZH, Exploding vs. imploding headache in migraine prophylaxis with botulinum toxin A. Pain 2006;125(3):286-95
   PubMed Web of Science ®Google Scholar
• Cady RK, Schreiber CP. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues. Headache 2008;48:900-13
   PubMed Web of Science ®Google Scholar
• Dodick DW, Aurora SK, Turkel CC, Botulinum toxin type A for treatment of chronic migraine: the double blind phase of the PREEMPT clinical program [abstract# P057]. Cephalalgia 2009;29(Suppl 1):34
   Google Scholar
• Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia 1997;17(2):103-8
   PubMed Web of Science ®Google Scholar
• Shaygannejad V, Janghorbani M, Ghorbani A, Comparison of the effect of topiramate and sodium valporate in migraine prevention: a randomized blinded crossover study. Headache 2006;46(4):642-8
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsandProviders/Drug SafetyInformationforHealthcare Professionals/ucm174949.htm
   Google Scholar
• Cady RK, Vause CV, Ho TW, Elevated saliva calcitonin gene-related peptide (CGRP) levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009;49(9):1258-66
   PubMed Web of Science ®Google Scholar
• Relja M, Poole AC, Schoenen J, A multicentre, double-blind, randomized, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of episodic migraine headaches. Cephalalgia 2007;27(6):492-503
   PubMed Web of Science ®Google Scholar
• Shuhendler AJ, Lee S, Siu M, Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo controlled trials. Pharmacotherapy 2009;29:784-91
   PubMed Web of Science ®Google Scholar
• Saper JR, Mathew NT, Loder EW, A double-blind, randomized, placebo-controlled comparison of botulinum toxin type a injection sites and doses in the prevention of episodic migraine. Pain Med 2007;8(6):478-85
   PubMed Web of Science ®Google Scholar
• Elkind AH, O'Carroll P, Blumenfeld A, A series of three sequential, randomized, controlled studies of repeated treatments with botulinum toxin type A for migraine prophylaxis. J Pain 2006;7:688-96
   PubMed Web of Science ®Google Scholar
• Evers S, Vollmer-Haase J, Schwaag S, Botulinum toxin A in the prophylactic treatment of migraine: a randomized, doubleblind, placebo-controlled study. Cephalalgia 2004;24:838-43
   PubMed Web of Science ®Google Scholar
• Ondo WG, Vuong KD, Derman HS. Botulinum toxin A for chronic daily headache: a randomized, placebocontrolled, parallel design study. Cephalalgia 2004;24:60-5
   PubMed Web of Science ®Google Scholar
• Dodick DW, Mauskop A, Elkind AH, Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis\ of patients not receiving other prophylactic medications:a randomized double-blind, placebo-controlled study. Headache 2005;45:315-24
   PubMed Web of Science ®Google Scholar
• Mathew NT, Frishberg BM, Gawel M, Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache 2005;45:293-307
   PubMed Web of Science ®Google Scholar